Nesiritide for the treatment of decompensated heart failure

Journal of Cardiac Failure

Volumn 7, Issue 1, 2001, Pages 92-100

  Colucci, W S ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B type natriuretic peptide; Myocardial failure; Natriuretic peptides; Vasodilator

Indexed keywords

NESIRITIDE; PLACEBO;

ADULT; AGED; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; HEART ARREST; HEART FAILURE; HEART OUTPUT; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; LUNG CAPILLARY PRESSURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR RESISTANCE;

EID: 0035073909     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2001.22999     Document Type: Article

References (34)

1. Cost-effectiveness analysis in clinical practice: The case of heart failure
2. Economic impact of heart failure in the United States: Time for a different approach
3. Management of patients hospitalized with heart failure
4. Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: A report from the cardiovascular and renal advisory panel of the Food and Drug Administration
5. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials
6. CNP is present in canine renal tubular cells and secreted by cultured opossum kidney cells
7. Natriuretic peptides in the pathophysiology of congestive heart failure
8. Atrial natriuretic factor: Its (patho)physiological significance in humans
9. 2+ATPase gene
10. Molecular and cellular mechanisms of myocardial failure
11. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide
12. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure
13. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells
14. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis
15. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts
16. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds
17. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart
18. Brain natriuretic peptide: Effect on left ventricular filling patterns in healthy subjects
19. Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion
20. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
21. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: Comparison with plasma angiotensin II and endothelin-1
22. Usefulness of a rapid, bedside test for brain natriuretic peptide in the evaluation of patients presenting to the emergency room with possible congestive heart failure
23. Pathophysiology of heart failure
24. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
25. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial
26. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
27. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial
28. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
29. Nesiritide is not associated with the proarrhythmic effects of dobutamine in the treatment of decompensated CHF: The PRECEDENT Study
30. Evidence of ventricular ectopy at baseline is not predictive of the proarrhythmic effects of dobutamine in the treatment of decompensated CHF: The PRECEDENT Study
31. The effect of shortterm therapy with nesiritide (B-type natriuretic peptide) or dobutamine on longterm survival
32. Demographic characteristics of patients in the VMAC trial (Vasodilation in the Management of Acute Congestive Heart Failure)
33. Results of the VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure
34. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure